CMT News & Updates
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
Filter by Category
Importance of Biomarkers in CMT
Using Biomarkers to Measure Effective Treatment Options for CMT
Targeting Axon Degeneration – a treatment for all types of CMT?
Preventing axon degeneration could stop the progression of CMT. Read about the efforts by pharma to stop axon degeneration.
Read More : Targeting Axon Degeneration – a treatment for all types of CMT?
Are We Prepared for Clinical Trials in Charcot-Marie-Tooth?
A Review of Clinical Trial Readiness for CMT BY CMT RESEARCH FOUNDATION'S SCIENTIFIC ADVISORY BOARD MEMBER DR. ALEXANDER ROSSOR Read the full paper In this issue of Brain Research, Mike…
Read More : Are We Prepared for Clinical Trials in Charcot-Marie-Tooth?
Partnership with DTx Pharma to optimize antisense oligonucleotides as a gene therapy for CMT1A
ATLANTA (December 20, 2019) The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company breaking open new…
A Robust Therapeutic Pipeline for CMT 1A
The majority of people with CMT have the 1A subtype which is due to duplication of the peripheral myelin protein 22 (PMP22) gene leading to breakdown of the myelin that…
Drug Screening in a Dish
At the CMT Research Foundation we are very much interested in using patient-derived stem cells called iPSCs for drug screening in order to develop therapies for CMT. Indeed, one of…
Gene Editing Used for the First Time in CMT
Gene editing as a therapeutic tool for treating disease has been very much in the news recently. The most commonly used gene editing tool to permanently fix the underlying genetic…
Chief Science Officer comments on recent work
CMT Research Foundation Chief Science Officer Grace Pavlath, PhD comments on recent work by Morelli et al: Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models Some…
Emerging Landscape of Modifier Genes in CMT
In CMT, there is a large variation in disease onset, severity, or progression, often seen among individuals with the same genetic subtype of a disease, even within a single family. …
Inherited Neuropathy Consortium Awarded $7.2M to Continue Studying, Improve Care for CMT
The National Institutes of Health has awarded the Inherited Neuropathies Consortium (INC) $7.2M over the next five years. This grant will be focused on improving clinical care and clinical research…
Read More : Inherited Neuropathy Consortium Awarded $7.2M to Continue Studying, Improve Care for CMT

